Mersana Therapeutics Inc Cash Flow Conversion Efficiency
Mersana Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Mersana Therapeutics Inc (MRSN) has a cash flow conversion efficiency ratio of 0.054x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.19 Million) by net assets ($-59.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Mersana Therapeutics Inc (2015–2024)
Cash flow conversion efficiency of Mersana Therapeutics Inc from 2015 to 2024. This chart illustrates how Mersana Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View MRSN stock price for real-time trading data and today's change.
Mersana Therapeutics Inc Cash Flow Conversion Ratio Explained
Mersana Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Mersana Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mersana Therapeutics Inc ranked by their cash flow conversion efficiency. Also see MRSN company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Humax Co. Ltd
KQ:115160
|
-0.018x |
|
Trada Maritime Tbk
JK:TRAM
|
0.009x |
|
Douglas Elliman Inc
NYSE:DOUG
|
-0.078x |
|
Traeger Inc
NYSE:COOK
|
0.102x |
|
Gevelot
PA:ALGEV
|
0.039x |
|
TYM Corporation
KO:002900
|
-0.078x |
|
Metal Powder Works Ltd
AU:MPW
|
-0.309x |
|
Federal Agricultural Mortgage Corporation
NYSE:AGM-A
|
0.022x |
Annual Cash Flow Conversion Efficiency for Mersana Therapeutics Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Mersana Therapeutics Inc from 2015 to 2024. Review Mersana Therapeutics Inc (MRSN) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-9.51 Million | $-82.34 Million | 8.659x | +289.22% |
| 2023-12-31 | $36.90 Million | $-168.88 Million | -4.576x | -753.42% |
| 2022-12-31 | $92.06 Million | $-49.36 Million | -0.536x | +53.37% |
| 2021-12-31 | $121.74 Million | $-139.99 Million | -1.150x | -251.12% |
| 2020-12-31 | $228.09 Million | $-74.70 Million | -0.327x | +62.14% |
| 2019-12-31 | $78.32 Million | $-67.74 Million | -0.865x | +86.22% |
| 2018-12-31 | $8.79 Million | $-55.22 Million | -6.278x | -929.62% |
| 2017-12-31 | $69.99 Million | $-42.68 Million | -0.610x | -7.36% |
| 2016-12-31 | $-55.62 Million | $31.59 Million | -0.568x | -351.62% |
| 2015-12-31 | $-42.69 Million | $-9.64 Million | 0.226x | -- |
About Mersana Therapeutics Inc
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial.… Read more